Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
HALEOSLABS

Haleos Labs Share Price

 

 

Haleos Labs live price: ₹1548.4. It opened at ₹1,564 vs previous close ₹1,565; intraday high/low: ₹1,564/₹1,518. The 50 & 200 DMA stand at ₹1,401.48/₹1,288.19.

Haleos Labs Performance

  • Today's Low
  • ₹1,518
  • Today's High
  • ₹1,564
  • 52 Week Low
  • ₹1,067
  • 52 Week High
  • ₹1,774
  • Open Price₹1,564
  • Previous Close₹1,565
  • Volume170
  • 50 DMA₹1,401.48
  • 100 DMA₹1,340.22
  • 200 DMA₹1,288.19

Haleos Labs Chart

Investment Returns

  • Over 1 Month + 19.67%
  • Over 3 Month + 19.77%
  • Over 6 Month + 19.02%
  • Over 1 Year + 11.96%

Smart Investing Starts Here Start SIP with Haleos Labs for Steady Growth!

Invest Now

Haleos Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 23.6
  • PEG Ratio
  • -1.7
  • Market Cap Cr
  • 468
  • P/B Ratio
  • 2.2
  • Average True Range
  • 92.19
  • EPS
  • 65.65
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 76.71
  • RSI
  • 57.92
  • MFI
  • 77.97

Haleos Labs Financials

Haleos Labs Technicals

EMA & SMA

Current Price
₹1,548.40
-16.3 (-1.04%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹1,504.76
  • 50 Day
  • ₹1,401.48
  • 100 Day
  • ₹1,340.22
  • 200 Day
  • ₹1,288.19

Resistance and Support

1579.97 Pivot Speed
  • R3 1,667.73
  • R2 1,643.57
  • R1 1,604.13
  • S1 1,540.53
  • S2 1,516.37
  • S3 1,476.93

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Haleos Labs Ltd has an operating revenue of Rs. 347.77 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 8% is okay, ROE of 10% is good. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 24% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 1% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Haleos Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-11 Quarterly Results
2025-11-10 Quarterly Results
2025-08-11 Quarterly Results & A.G.M.
2025-05-29 Audited Results & Dividend
2025-02-12 Quarterly Results & Others To consider other business matters. per share(15%)Dividend
Date Purpose Remarks
2025-09-24 FINAL Rs.1.50 per share(15%)Dividend
View Haleos Labs Dividend History Arrow

Haleos Labs Shareholding Pattern

72.11%
0%
24.33%
3.56%

Haleos Labs FAQs

Haleos Labs share price is ₹1,548 As on 18 May, 2026 | 13:04

The Market Cap of Haleos Labs is ₹468.1 Cr As on 18 May, 2026 | 13:04

The P/E ratio of Haleos Labs is 23.6 As on 18 May, 2026 | 13:04

The PB ratio of Haleos Labs is 2.2 As on 18 May, 2026 | 13:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23